Because of high percent of failures in haematologic malignancies treatment there is a need of discovering new drugs. One of the new approaches are monoclonal antibodies, which target specific cluster differentiation antigens on tumor cells. Rituximab is an anti-CD20 antibody used in non-Hodgkin lymphoma, alemtuzumab - in B chronic lymphocytic leukaemia, gemtuzumab ozogamicin ? in non-lymphoblastic leukaemia, tositumomab and ibritumomab are monoclonal antibodies binded with radiopharmaceutics and are used in non-Hodgkin lymphomas.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.